Recent Translated Articles from The Oncologist

Volume 22, Number 9, September 2017

Clinical Trial Results

A Phase Ib Dose‐Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS
Christopher H. Lieu, Manuel Hidalgo, Jordan D. Berlin, Andrew H. Ko, Andres Cervantes, Patricia LoRusso, David E. Gerber, J. Paul Eder, S. Gail Eckhardt, Amy V. Kapp, Amy Tsuhako, Bruce McCall, Andrea Pirzkall, Anne Uyei, Josep Tabernero
The Oncologist 2017; 22:1024-e89; first published on June 7, 2017; doi:10.1634/theoncologist.2017-0175

Endogenous Heat‐Shock Protein Induction with or Without Radiofrequency Ablation or Cryoablation in Patients with Stage IV Melanoma
Evidio Domingo‐Musibay, James M. Heun, Wendy K. Nevala, Matthew Callstrom, Thomas Atwell, Evanthia Galanis, Lori A. Erickson, Svetomir N. Markovic
The Oncologist 2017; 22:1026-e93; first published on July 5, 2017; doi:10.1634/theoncologist.2017-0060

Breast Cancer

Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field
Clinton Yam, Sendurai A. Mani, Stacy L. Moulder
The Oncologist 2017; 22:1086-1093; first published on May 30, 2017; doi:10.1634/theoncologist.2017-0095

Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA‐3 Results
Sibylle Loibl, Nicholas C. Turner, Jungsil Ro, Massimo Cristofanilli, Hiroji Iwata, Seock‐Ah Im, Norikazu Masuda, Sherene Loi, Fabrice André, Nadia Harbeck, Sunil Verma, Elizabeth Folkerd, Kathy Puyana Theall, Justin Hoffman, Ke Zhang, Cynthia Huang Bartlett, Mitchell Dowsett
The Oncologist 2017; 22:1028-1038; first published on June 26, 2017; doi:10.1634/theoncologist.2017-0072

Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin‐Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations
Laura M. Spring, Mark L. Zangardi, Beverly Moy, Aditya Bardia
The Oncologist 2017; 22:1039-1048; first published on July 13, 2017; doi:10.1634/theoncologist.2017-0142


The Impact of a Hepatobiliary Multidisciplinary Team Assessment in Patients with Colorectal Cancer Liver Metastases: A Population‐Based Study
Jennie Engstrand, Nikolaos Kartalis, Cecilia Strömberg, Mats Broberg, Anna Stillström, Tobias Lekberg, Eduard Jonas, Jacob Freedman, Henrik Nilsson
The Oncologist 2017; 22:1067-1074; first published on May 26, 2017; doi:10.1634/theoncologist.2017-0028

Lung Cancer

Real‐World Data on Prognostic Factors for Overall Survival in EGFR Mutation‐Positive Advanced Non‐Small Cell Lung Cancer Patients Treated with First‐Line Gefitinib
Zong‐Han Yao, Wei‐Yu Liao, Chao‐Chi Ho, Kuan‐Yu Chen, Jin‐Yuan Shih, Jin‐Shing Chen, Zhong‐Zhe Lin, Chia‐Chi Lin, James Chih‐Hsin Yang, Chong‐Jen Yu
The Oncologist 2017; 22:1075-1083; first published on May 15, 2017; doi:10.1634/theoncologist.2016-0331

Symptom Management and Supportive Care

Transitions in Prognostic Awareness Among Terminally Ill Cancer Patients in Their Last 6 Months of Life Examined by Multi‐State Markov Modeling
Chen Hsiu Chen, Fur‐Hsing Wen, Ming‐Mo Hou, Chia‐Hsun Hsieh, Wen‐Chi Chou, Jen‐Shi Chen, Wen‐Cheng Chang, Siew Tzuh Tang
The Oncologist 2017; 22:1135-1142; first published on July 6, 2017; doi:10.1634/theoncologist.2017-0068